Beijing-based BioGeometry raises more than $100M for AI drug discovery

Oct 28, 2026 · Issue 13 · 2 sources, 2 articles

Beijing-based BioGeometry has secured more than $100 million in funding for AI-based drug discovery. The news was reported on 28 October.

Who is affected and how

pharmaceuticals

Capital flowing to Chinese AI drug-discovery companies is also expanding the licensing and partnering market.

Sources

• Beijing-based BioGeometry gets $100M+ for AI drug R&Dendpoints news · Oct 28, 2026
• BioGeometry raises $100M in Series A extension for its AI drug-design modelsdealroom · Oct 29, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.